This preprint is under consideration at Cancer Nanotechnology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
YUANZHI LI
xi nan yi ke da xue: Southwest Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
The problems associated with poor water solubility of anticancer drugs are one of the most important challenges in achieving effective cancer therapy. The present study was designed to evaluate the effect of Scutellarein on human colon cancer cells in vitro by using a target αvβ-3 novel Scutellarein (Scu)-loaded niosome nanoparticle (β-CD-CL-Scu-cRGD).
Results
β-CD-CL-Scu-cRGD has a diameter of 140.2nm and a zeta potential of -11.3 mV with a constant physicochemical stability. The MTT assay showed both Scu and β-CD-CL-Scu-cRGD caused a decrease in cell proliferation and viability of HT29, but β-CD-CL-Scu-cRGD showed better activity in vitro. Colony formation assay and flow cytometry assay showed that β-CD-CL-Scu-cRGD has a better effect on cell proliferation and apoptosis.
Conclusions
Although further in vivo studies are necessary, our results suggested that β-CD-CL-Scu-cRGD could be an outstanding carrier to deliver Scu for potential therapeutic approaches into colon cancer.
Keywords
Scutellarein, nanoparticles, colon cancer, β-cyclodextrin, αvβ3
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 11 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 12 Apr, 2021
Reviewer #2 agreed
On 15 Mar, 2021
Review #2 received
Received 15 Mar, 2021
Reviewers invited
Invitations sent on 14 Mar, 2021
Reviewer #1 agreed
On 14 Mar, 2021
Review #? received
Received 14 Mar, 2021
Editor assigned
On 05 Mar, 2021
Submission checks complete
On 05 Mar, 2021
Editor invited
On 05 Mar, 2021
First submitted
On 22 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Cancer Nanotechnology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
YUANZHI LI
xi nan yi ke da xue: Southwest Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 11 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 12 Apr, 2021
Reviewer #2 agreed
On 15 Mar, 2021
Review #2 received
Received 15 Mar, 2021
Reviewers invited
Invitations sent on 14 Mar, 2021
Reviewer #1 agreed
On 14 Mar, 2021
Review #? received
Received 14 Mar, 2021
Editor assigned
On 05 Mar, 2021
Submission checks complete
On 05 Mar, 2021
Editor invited
On 05 Mar, 2021
First submitted
On 22 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
The problems associated with poor water solubility of anticancer drugs are one of the most important challenges in achieving effective cancer therapy. The present study was designed to evaluate the effect of Scutellarein on human colon cancer cells in vitro by using a target αvβ-3 novel Scutellarein (Scu)-loaded niosome nanoparticle (β-CD-CL-Scu-cRGD).
Results
β-CD-CL-Scu-cRGD has a diameter of 140.2nm and a zeta potential of -11.3 mV with a constant physicochemical stability. The MTT assay showed both Scu and β-CD-CL-Scu-cRGD caused a decrease in cell proliferation and viability of HT29, but β-CD-CL-Scu-cRGD showed better activity in vitro. Colony formation assay and flow cytometry assay showed that β-CD-CL-Scu-cRGD has a better effect on cell proliferation and apoptosis.
Conclusions
Although further in vivo studies are necessary, our results suggested that β-CD-CL-Scu-cRGD could be an outstanding carrier to deliver Scu for potential therapeutic approaches into colon cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...